Investee Profile

First-in-class and disruptive

Our approach targets a well-defined customer base: partners that seek to access external innovation. The signature of the investment sweet spot for us is thus primarily defined by their needs for first-in-class products that address a clear market need. In our portfolio companies thus we seek to develop technologies and products with disruptive potential. Preferably such assets are at preclinical stage, and even conceptual research stage such that, together with the (scientific) founders, a lean business case can be implemented at day one.

Scalable technologies

Capital-efficient leverage of a business case is a key driver in our strategy. This approach works particularly well when the potential of a technology is demonstrated through an exemplary development success. We therefore seek to execute a strategy around technologies that have the potential to form the basis for multiple products. Hence the value generated as part of our investment lies partly in the lead product that is based on such technology, but considerable additional value is created in validating the underlying technology.

"Stefan Herr was instrumental not only throughout the creation and founding of Cenix, from the very first conceptual discussions to the launch of the new legal corporate entity back in 1999, but importantly also in the conclusion of both of our subsequent VC investment rounds. The path of a first-time Biotech entrepreneur is a very challenging one for anyone to take, but would have been literally impossible for me without Stefan's support, guidance and mentoring as the company's business co-founder. This served me well, as I continue learning every day, now, in the 10th year of Cenix."
Chris Echeverri, Ph.D.; CEO/CSO, lead scientific founder of Cenix BioScience, Dresden